H-Gemcitabine: A new gemcitabine prodrug for treating cancer

Madhuri Dasari, Abhinav P. Acharya, Dongin Kim, Seungjun Lee, Sungmun Lee, Jeanne Rhea, Ross Molinaro, Niren Murthy

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

Original languageEnglish (US)
Pages (from-to)4-8
Number of pages5
JournalBioconjugate chemistry
Volume24
Issue number1
DOIs
StatePublished - Jan 16 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Fingerprint Dive into the research topics of 'H-Gemcitabine: A new gemcitabine prodrug for treating cancer'. Together they form a unique fingerprint.

  • Cite this

    Dasari, M., Acharya, A. P., Kim, D., Lee, S., Lee, S., Rhea, J., Molinaro, R., & Murthy, N. (2013). H-Gemcitabine: A new gemcitabine prodrug for treating cancer. Bioconjugate chemistry, 24(1), 4-8. https://doi.org/10.1021/bc300095m